Abstract: Compound (A) can be used for increasing the yield of useful plants or crop plants with respect to their harvested plant organs, wherein the Compound (A) is selected from compounds of the formula (I) or salts thereof, in which R1 are identical or different and are halogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, nitro or (C1-C4)-haloalkyl, n is an integer from 0 to 5, R2 is OR5, SR6 or NR7R8 or a saturated or unsaturated 3- to 7-membered heterocycle having at least one nitrogen atom and up to 3 heteroatoms, preferably selected from the group consisting of O and S, which is attached to the carbonyl group in formula (I) via the nitrogen atom and which is unsubstituted or substituted by radicals selected from the group consisting of (C1-C4)-alkyl, (C1-C4)-alkoxy and unsubstituted or substituted phenyl, R5, R6, R7 independently of one another are hydrogen or an unsubstituted or substituted aliphatic hydrocarbon radical, and R8 is hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy or substituted or unsubstituted phenyl, R10 is hy

Abstract: An adjustable equestrian saddle and adjusting and reinforcing system for adjusting an equestrian saddle to permit the saddle fit several sizes of the back and withers of one or more horses, wherein the adjusting system comprises a plurality of reinforcing members having different angular dimensions with the saddle having a headplate for interchangeably receiving the reinforcing members and a lid to have access to the reinforcing members.

Abstract: Compounds (A) can be used for increasing the yield of useful plants or crop plants with respect to their harvested plant organs, wherein the Compound (A) is selected from compounds of the formula (I) or salts thereof, in which (R1)n is n radicals R1 where the R1 are identical or different and are each halogen or (C1-C4)-haloalkyl, n is an integer from 1 to 3, R2 is hydrogen, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C6)-cycloalkyl, tri-(C1-C4)-alkyl-silyl or tri-(C1-C4)-alkyl-silylmethyl, R3 is hydrogen, (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl or (C3-C6)-cycloalkyl, and R4 is hydrogen or (C1-C12)-alkyl, preferably mefenpyr-diethyl (Compound (A1)]

Abstract: An adjustable equestrian saddle and adjusting and reinforcing system for adjusting an equestrian saddle to permit the saddle fit several sizes of the back and withers of one or more horses, wherein the adjusting system comprises a plurality of reinforcing members having different angular dimensions with the saddle having a headplate for interchangeably receiving the reinforcing members.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: A saddle for horses which is adapted to the body of the equine by means of a set of pads comprising a structured filling with a spongy material of fibers and a layer of a neoprene material, where such set of pads homogeneously distribute strains and temperatures which are generated on the back of them, preventing possible fatigues and chronic pains caused by the weight of the horseman during and after a physical effort.

Abstract: An adjustable equestrian saddle and adjusting and reinforcing system for adjusting an equestrian saddle to permit the saddle fit several sizes of the back and withers of one or more horses, wherein the adjusting system comprises a plurality of reinforcing members having different angular dimensions with the saddle having a headplate for interchangeably receiving the reinforcing members and a lid to have access to the reinforcing members.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

Abstract: The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: An adjustable equestrian saddle and adjusting and reinforcing system for adjusting an equestrian saddle to permit the saddle fit several sizes of the back and withers of one or more horses, wherein the adjusting system comprises a plurality of reinforcing members having different angular dimensions with the saddle having a headplate for interchangeably receiving the reinforcing members.

Abstract: An assembly for training and/or instruction of horses, for maintaining, building-up and improving the muscles and stance and posture of the horse by making the animal to walk or trot in the correct positions and stances, with the assembly comprising a girth fixed to the breast portion of the animal's body, the girth having a plurality of connecting points to which a rear cord and side cords are connected, with both cords connected to a rear tensor, wherein the cords and the tensor forces the animal to adopt a desired stance during the training thereof.

Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-? and IL-15, are reduced.

Abstract: The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: (i) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (ii) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle. Preferably the immunogen is administered in the form of a pharmaceutical composition. Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

Abstract: The invention relates to the use of an immunogen selected from the group consisting of